Genomic Aberrations in Circulating Tumor DNAs from Palbociclib-Treated Metastatic Breast Cancer Patients Reveal a Novel Resistance Mechanism

SIMPLE SUMMARY: The combination of CDK4/6 inhibitors and endocrine therapy is now considered the standard of care for patients with estrogen receptor-positive (ER(+)) breast cancer. The emerging tide of CDK4/6 inhibitor resistance urges more research to explore underlying resistance mechanisms. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Abu-Khalaf, Maysa, Wang, Chun, Zhang, Zhenchao, Luo, Rui, Chong, Weelic, Silver, Daniel P., Fellin, Frederick, Jaslow, Rebecca, Lopez, AnaMaria, Cescon, Terrence, Jiang, Wei, Myers, Ronald, Wei, Qiang, Li, Bingshan, Cristofanilli, Massimo, Yang, Hushan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221535/
https://www.ncbi.nlm.nih.gov/pubmed/35740538
http://dx.doi.org/10.3390/cancers14122872

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221535/
https://www.ncbi.nlm.nih.gov/pubmed/35740538
http://dx.doi.org/10.3390/cancers14122872

Ejemplares similares